Pharmaceuticals - Mexico

  • Mexico
  • The Pharmaceuticals market in Mexico is expected to reach a revenue of US$7.39bn in 2024.
  • The largest market in the country is Oncology Drugs, with a projected market volume of US$1.24bn in the same year.
  • The revenue is anticipated to grow at an annual growth rate (CAGR 2024-2029) of 4.37%, resulting in a market volume of US$9.15bn by 2029.
  • In comparison to other countries, United States is projected to generate the highest revenue of US$630.30bn in 2024.
  • Mexico's pharmaceutical market is experiencing a surge in demand for generic drugs due to increasing healthcare costs.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Pharmaceuticals market in Mexico has been experiencing growth in recent years, with a steady increase in demand for prescription drugs and over-the-counter medications.

Customer preferences:
Mexican consumers are becoming more health-conscious and are willing to invest in their well-being. This has led to an increase in demand for preventative medications and supplements, as well as prescription drugs for chronic conditions such as diabetes and hypertension. Additionally, there is a growing interest in alternative medicine and natural remedies, which has created opportunities for companies offering these products.

Trends in the market:
One of the main trends in the Mexican Pharmaceuticals market is the increasing use of e-commerce platforms to purchase medications. This trend has been accelerated by the COVID-19 pandemic, which has led to a rise in online shopping across all industries. Another trend is the growing importance of generic drugs, which are more affordable than brand-name medications and are becoming increasingly popular among consumers.

Local special circumstances:
Mexico has a large population with a high prevalence of chronic diseases such as diabetes and hypertension. This has created a significant demand for prescription medications, particularly in rural areas where access to healthcare is limited. Additionally, the Mexican government provides free healthcare to a large portion of the population, which has led to a high demand for affordable medications.

Underlying macroeconomic factors:
Mexico's pharmaceutical market is expected to continue growing due to several macroeconomic factors. The country has a large and growing middle class with increasing purchasing power, which is driving demand for healthcare products and services. Additionally, Mexico has a young and growing population, which is expected to increase demand for healthcare in the coming years. Finally, the Mexican government has implemented policies to encourage foreign investment in the pharmaceutical sector, which is expected to further stimulate growth in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Next generation therapy
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)